We show here, using β1-adrenergic receptors, that β-arrestin-2 (arrestin 3) accumulates robustly in CCSs after dissociating from its activating GPCR and transduces the MAP kinase signal from CCSs. Moreover, inhibiting subsequent endocytosis of CCSs enhances the clathrin-and β-arrestin-dependent MAP kinase signal. These results demonstrate β-arrestin 'activation at a distance', after dissociating from its activating GPCR, and signalling from CCSs. We propose a β-arrestin signalling cycle that is catalytically activated by the GPCR and energetically coupled to the endocytic machinery.
Our motivation to investigate β-arrestin function in living cells stemmed from an intriguing discordance between in vivo and in vitro observations regarding the G-protein-independent signalling wave. In vivo, β1-adrenergic receptors (β1ARs) mediate signalling via the ERK1/2 MAP kinase through β-arrestin that is essential for promoting cardiac muscle cell survival under conditions of strong adrenergic drive 10 . In vitro, however, β1ARs are poorly phosphorylated and weakly engage β-arrestin [11] [12] [13] and, at the cellular level, β1ARs are internalized poorly, if at all, by clathrin-mediated endocytosis 11, 14 (CME). This confluence of seemingly contradictory observations presented a puzzle relative to the prevailing current view of β-arrestin function, motivating us to directly test its underlying tenets.
FLAG-tagged β1ARs expressed in human embryonic kidney (HEK 293) cells failed to detectably internalize (Fig. 1a ,b, red symbols) or cluster in the plasma membrane (Fig. 1c,d , red lines) after activation by the β-adrenergic agonist isoproterenol. In contrast, β2-adrenergic receptors (β2ARs) internalized and clustered robustly ( Fig. 1a-d , blue symbols and lines). Despite failing to undergo detectable CME, β1ARs clearly activated ERK1/2 ( Fig. 1e) and did so to a similar degree as β2ARs when compared in expression-matched cell clones ( Supplementary Fig. 1a-c) . Further, the β1AR-mediated ERK1/2 response was dependent on both β-arrestin-2 ( Fig. 1e ,f) and clathrin heavy chain ( Supplementary  Fig. 1d ). We verified that this effect was indeed mediated by β1ARs by using the β1-selective agonist dobutamine, and verified specificity of both the β-arrestin-2 and clathrin knockdown effects by transgenic rescue using RNA interference-resistant constructs ( Supplementary Fig. 1d-g ).
This raised the question of how a GPCR that is not internalized by CME generates a MAP kinase signal requiring both β-arrestin and clathrin. To address this question, we visualized in living cells the localization of all three proteins using triple-label total internal reflection fluorescence microscopy (TIR-FM). β1ARs remained diffusely distributed in the plasma membrane after application of the β1-selective agonist dobutamine but, unexpectedly, β-arrestin-2 was robustly recruited to spots at the plasma membrane that co-localized with clathrin ( Fig. 2a and Supplementary Video 1). Robust recruitment of β-arrestin-2, but not β1ARs, to CCSs was also evident by line scan analysis (Fig. 2b) and by visual inspection of individual examples (Fig. 2c) .
β1AR activation drove rapid recruitment of β-arrestin-2 to essentially all CCSs in the plasma membrane, including diffractionlimited spots that include bona fide clathrin-coated pits (CCPs) (f) Quantification of ERK1/2 activation by normalizing phosphorylated ERK1/2 to total ERK1/2 and determining fold change over untreated (n = 3 independent experiments, * P = 0.0386 by two-tailed t-test). Error bars correspond to s.e.m. Raw data of independent repeats are in Supplementary Table 1 . Panels c-e show results that are representative from three independent experiments. Unprocessed original scans of western blots are shown in Supplementary Fig. 6 .
but also larger structures that correspond to flat clathrin lattices or plaques 15 . We observed the same behaviour in COS cells, another kidney-derived cell line in which diffraction-limited clathrin spots correspond largely to CCPs (refs 16,17; Fig. 2d and Supplementary Video 2). A remarkable property of β-arrestin-2 is that it associates with pre-existing CCSs in response to GPCR activation, in contrast to constitutive endocytic adaptors that must co-assemble at an early stage of CCS formation 18, 19 . β1AR activation clearly drove β-arrestin-2 association with pre-existing CCSs ( Supplementary Fig. 2a,b ), but we also observed β-arrestin-2 association with clathrin spots as they form, most likely representing association at an early stage of CCS assembly ( Supplementary Fig. 2c,d ). Whereas β-arrestin-2 extensively overlapped with plasma membrane CCSs, there was no detectable recruitment to clathrin associated with Golgi elements or endosomes that dynamically appear in the TIR-FM imaging field ( Supplementary  Fig. 2e and Supplementary Video 3). Diffraction-limited CCSs were typically seen to abruptly disappear from the evanescent illumination field ( Supplementary Fig. 2f,g ), consistent with endocytic scission of CCPs and coincident dissociation of β-arrestin-2 as shown previously 18, 19 .
We further characterized β-arrestin-2-associated CCSs using two methods of super-resolution imaging. First, we applied photoactivated localization microscopy (PALM) to image β-arrestin-2 clusters formed after β1AR activation in both HEK 293 ( Supplementary Fig. 3a ) and COS cells ( Supplementary Fig. 3b ). β-Arrestin-2 localized to structures smaller than 100 nm, consistent with bona fide CCPs as originally defined morphologically, as well as larger structures ( Supplementary Fig. 3c,d) . A similar size distribution was found by PALM localization of clathrin light chain. Both distributions had a peak at 60-90 nm but also included smaller and larger structures in lower relative number ( Supplementary Fig. 3e ). Second, we applied two-colour structured illumination microscopy to examine β-arrestin-2 localization relative to clathrin in the same living cells. β-Arrestin-2 co-localized extensively with clathrin in structures of variable size, including those less than or equal to ∼100 nm as well as larger structures, with similar results observed in HEK 293 ( Supplementary Fig. 3f,g ) and COS cells ( Supplementary Fig. 3h,i ). Together these observations indicate that β1AR activation drives β-arrestin-2 recruitment to a heterogeneous population of plasma membrane CCSs. We verified that β-arrestin-2 recruitment to CCSs is indeed mediated specifically by ligand-induced activation of β1ARs both pharmacologically and genetically. Dobutamine-elicited recruitment of β-arrestin-2 to CCSs was concentration-dependent within a range consistent with known β1AR pharmacology 20 and blocked by CGP20712A, a highly selective β1AR antagonist ( Fig. 2e-g ). Providing genetic proof of specificity, dobutamine failed to elicit detectable recruitment of β-arrestin-2 in cells not expressing β1ARs (Fig. 2h) .
The ability of β1ARs to drive robust localization of β-arrestin-2 to CCSs without detectably concentrating there suggested that the β1AR does not accumulate at CCSs stoichiometrically with activated arrestin. This is contrary to the current dogma, which holds that GPCRs accumulate in CCSs together with β-arrestin-2 in a stoichiometric complex. To explicitly test this, we compared the behaviour of the β1AR to that of the efficiently clustered β2AR. We reasoned that, if β1ARs indeed accumulate in CCSs substoichiometrically relative to β-arrestin-2, then the intensity of the β1AR fluorescence signal at CCSs after ligand-induced activation should be significantly weaker than the signal of the identically labelled β2ARs, when measured in expression-matched cells and under identical conditions. This was indeed the case. With identical labelling and imaging conditions, and using cell populations carefully matched for β-arrestin-2 and receptor expression (Fig. 3a,b) , β1ARs and β2ARs were indistinguishable in their ability to drive β-arrestin-2 recruitment to CCSs (Fig. 3c ) but these GPCRs differed markedly in their ability to accumulate in CCSs (Fig. 3d ). β1ARs were not significantly enriched at CCSs on the basis of calculation of the 95% confidence interval (Fig. 3e) . In marked contrast, β2ARs were strongly enriched in a time-dependent manner, exceeding the 95% confidence interval by more than two orders of magnitude within several minutes after receptor activation (Fig. 3f) . As further verification, and to rule out the possibility that observed differences resulted spuriously from receptor overexpression (such as saturation of a limiting CCSassociated component), we quantified receptor enrichment in CCSs across individual cells expressing receptors over a wide range. The starkly different behaviour of β1ARs relative to β2ARs was verified at all levels of relative receptor expression achieved (Fig. 3g, see  arrows) . Although we cannot exclude the possibility that some small number of β1ARs are indeed present in CCSs, it is clear that β1ARs accumulate to a much smaller degree than β2ARs, despite driving comparable β-arrestin-2 recruitment to CCSs. Thus, β1ARs could not possibly be present in CCSs in stoichiometric complex with β-arrestin-2.
To determine whether β1ARs can drive β-arrestin trafficking to CCSs without themselves moving there, we immobilized receptors in the plasma membrane by surface crosslinking with polyclonal antibodies 21 and verified lateral immobilization by fluorescence recovery after photobleaching ( Supplementary Fig. 4a,b) . Immobilized β1ARs formed clusters that predominantly localized separate from CCSs (Fig. 3h) . Nevertheless, immobilized β1ARs still promoted robust recruitment of β-arrestin-2 to CCSs, evident within 20 s after application of dobutamine, whereas β1AR clusters remained separate and immobile ( Fig. 3h and Supplementary Videos 4 and 5). β1AR-elicited recruitment of β-arrestin-2, but not of β1ARs, to CCSs was visibly apparent in individual examples (Fig. 3i) , verified by line scan analysis (Fig. 3j) and further verified across multiple experiments by time-dependent correlation analysis (Fig. 3k) . Thus, ligand-activated β1ARs can indeed promote robust trafficking of β-arrestin-2 to CCSs without themselves moving there. These results demonstrate that β-arrestin-2 can traffic separately from its upstream activating GPCR-a behaviour previously not thought possible.
We next asked whether this discrete trafficking behaviour of β-arrestin-2 can explain how β1ARs drive β-arrestin-2-and clathrindependent ERK1/2 activation without internalizing. The prevailing view is that ligand-activated GPCRs internalize together with β-arrestin in complex, and that internalization of the formed complex is required for full β-arrestin-mediated ERK1/2 activation. Given that β1ARs drive β-arrestin-2 trafficking to CCSs but not to internal membrane structures, we considered the alternative possibility that β-arrestin-2 might activate ERK1/2 from CCSs rather than endosomes. Knockdown of β-arrestin-2 markedly inhibited the magnitude of β1AR-elicited ERK1/2 activation but did not detectably affect its kinetics ( Supplementary Fig. 5a ,b), a result consistent with either hypothesis.
We distinguished these hypotheses by examining the effect of Dyngo-4a, a hydroxylated form of dynasore that acutely blocks all dynamin-dependent endocytic routes including CME (ref. 22) . Acute endocytic blockade did not inhibit β1AR-elicited ERK1/2 activation, contrary to expectation based on the prevailing current view. In fact, endocytic blockade enhanced the β1AR-elicited ERK1/2 response (Fig. 4a-c) , and this was specific to the β1AR-elicited signalling because Dyngo-4a did not affect the basal signal detected in the absence of β1AR agonist ( Supplementary Fig. 5c ). Further, we verified that Dyngo-4a had no detectable effect in cells depleted of β-arrestin-2 ( Fig. 4d-f) , excluding off-pathway effects of Dyngo-4a in the present interpretation. These observations favour the hypothesis that β-arrestin-2 activated by β1ARs initiates signalling from CCSs rather than endosomes. Dyngo-4a blocks not only CME but also a recently identified clathrin-independent endocytic route (FEME). However, FEME does not require β-arrestin-2 or clathrin 23 . We found that the β1AR-elicited ERK1/2 signal requires both (as shown in Fig. 1e,f and Supplementary Figs 1d,e and 5a,b) , thus excluding FEME as a potential mechanism of the β1AR-elicited ERK1/2 response.
We were intrigued by the observation that Dyngo-4a not only enhanced the maximum degree of β1AR-elicited ERK1/2 activation, but also significantly extended the duration of the ERK1/2 signal ( Supplementary Fig. 5d,e) . Dyngo-4a, by blocking dynamin activity, effectively stalls CCSs on the plasma membrane 22, 24, 25 and thereby extends the surface lifetime of recruited β-arrestin-2 ( Supplementary  Fig. 5f ). This suggested the possibility that CCSs, in addition to serving as sites of ERK1/2 activation by β-arrestin-2, might also shape the kinetics of β1AR-elicited ERK1/2 signalling according to CCS surface lifetime. To test whether this might be relevant to ERK1/2 signalling elicited by β1ARs under normal conditions, we examined the effect of β1AR activation on the surface lifetime of CCSs in cells not exposed to Dyngo-4a. When diffraction-limited β-arrestin-2 clusters were identified separately from larger structures (Fig. 5a,b; representative examples are shown in regions outlined by ovals and rectangles, respectively), we noticed that their surface lifetime was longer after β1AR activation (Fig. 5c) . We verified this observation across multiple specimens and experiments by blinded manual scoring (Fig. 5d,e) and using automated analysis software (cmeAnalysis) developed and validated previously by others 26 (Fig. 5f ). As an independent and inherently unbiased confirmation, β1AR activation also significantly reduced endocytic uptake of labelled transferrin, a constitutive cargo of CME, thus providing an orthogonal biochemical metric of CME dynamics (Fig. 5g) .
Together, the present results reveal a remarkable new aspect of β-arrestin biology. The previous understanding, which we call 'activation from the complex' , is based on the tenets that β-arrestin operates in obligate physical complex with an activated GPCR and its signalling activity requires endocytosis of the formed complex (Fig. 5h) . We show a different behaviour using β1ARs as a relevant model GPCR, which we call 'activation at a distance' , where β-arrestin traffics to CCSs separately from its activating GPCR and promotes MAP kinase activation from CCSs before endocytic scission (Fig. 5i) . Our results also demonstrate a role for CCS surface dynamics as a physiological control point for β-arrestin signalling, thus revealing an additional relationship between cellular signalling and membrane trafficking that may be relevant more widely in the GPCR family (for example, refs 25,27,28) .
This newly recognized trafficking and signalling behaviour of β-arrestin raises many additional questions, particularly regarding the molecular mechanism. Our observations support the hypothesis that β-arrestin undergoes conformational activation through transient contact with an activated GPCR and then dissociates from the GPCR to subsequently bind CCPs while still in a conformationally activated state. We propose that this supports a β-arrestin signalling cycle that is analogous, in overall biochemical logic, to the conventional G protein cycle. In the G protein cycle, the activated GPCR acts as a catalyst for G protein conformational activation, and the cycle is energetically driven by guanine nucleotide hydrolysis through intramolecular coupling to an intrinsic GTPase activity (Fig. 5j , top, catalytic GPCR activity is denoted as R * ). We propose that β-arrestin conformational activation is also catalysed by activated GPCRs, but the energetics of β-arrestin signalling are provided by intermolecular coupling to the endocytic cycle involving dynamic CCP assembly, scission and dissociation. Although different in its biochemical details, this energetic cycle is also fundamentally powered by nucleotide hydrolysis, including that mediated by the dynamin GTPase (Fig. 5j, bottom) . Intermolecular coupling between the β-arrestin and endocytic cycles is possible because conformational activation of arrestin releases its carboxy-terminal tail, which in β-arrestins is a binding site for the assembled CCP lattice [29] [30] [31] . Further extending the analogy, the dynamin GTPase operating in the coupled cycle of β-arrestin signalling is positioned similarly to the GTPaseactivating protein (GAP) activity operating in the conventional G protein cycle. This explains why inhibiting dynamin enhances the β-arrestin-mediated MAP kinase signal, just as inhibiting the GAP enhances the G-protein-mediated cAMP signal, and how CCP lifetime controls the magnitude and kinetics of downstream β-arrestin-mediated signalling. Figure 5 Relationship between β-arrestin signalling and CME dynamics. (a,b) Activation of FLAG-β1ARs (a) or FLAG-β2ARs (b) produced similar recruitment of β-arrestin-2-GFP to CCSs. Examples outlined by ovals indicate diffraction-limited spots representing individual CCSs. Examples outlined by rectangles indicate structures larger than the diffraction limit that were excluded from analysis as they represent groups of CCSs or clathrin plaques. Scale bars, 5 µm. (c) Representative image series of individual arrestin-associated CCSs observed by TIR-FM after β1AR (top row) or β2AR (bottom row) activation. Images were collected at 0.5 Hz and, for brevity of presentation, one in eight frames (16 s interval) is shown. Scale bar, 500 nm. (d) Average surface lifetime of β-arrestin-2 clusters after the indicated receptor activation (whiskers represent minimum and maximum, boxplot represents median, and 25th and 75th quartiles; n = 150 CCSs pooled across three independent experiments for β1AR and n = 100 CCSs pooled across two independent experiments for β2AR, * * * P = 0.0001). (e) Frequency distribution analysis of the β-arrestin-2 surface lifetimes shown in d. (f) Automated cmeAnalysis of CCS lifetimes in cells expressing FLAGβ1ARs with and without 10 µM dobutamine treatment (n = 3 independent experiments, * P = 0.0165). (g) Cellular uptake of transferrin after the indicated receptor activation (n = 3 independent experiments, * * P = 0.0025). Error bars represent s.e.m.; P values calculated by a two-tailed t-test. Raw data from independent repeats are provided in Supplementary Table 1. (h,i) Schematic summarizing the prevailing current view of cellular β-arrestin function, based on 'activation from the complex' (h). The additional mode of β-arrestin trafficking and signalling, 'activation at a distance', is demonstrated in the present study (i). Here, β-arrestin operates after dissociating from its activating GPCR rather than in physical complex with it, and the ERK signal is initiated from CCSs rather than endosomes. (j) Schematic of the conventional G protein signalling mechanism based on allosteric coupling to GTP hydrolysis (top) and the proposed β-arrestin signalling mechanism based on intermolecular coupling to the CME cycle (bottom). Activated GPCR form(s) catalysing the indicated conformational activations are denoted as R * .
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METHODS
Cell culture, expression constructs and transfections. HEK 293 and COS-1 cells (purchased from ATCC as the authenticated lines CRL-1573 and CRL-1650, respectively) were cultured in complete growth Dulbecco's modified Eagle's medium (DMEM, Gibco) and supplemented with 10% fetal bovine serum (UCSF Cell Culture Facility). Cell cultures were free of mycoplasma contamination.
Amino-terminally FLAG-tagged versions of the human β1AR and β2AR were cloned into pcDNA3.0 (refs 32,33). Super ecliptic pHluorin (SEP)-β1AR was generated by PCR amplification of SEP and in-frame insertion into the FLAG-β1AR construct. β-Arrestin-2-GFP was a gift from M. Caron (Duke University, USA) and previously described 34 . β-Arrestin-2-mApple was generated by subcloning β-arrestin-2 into pmApple-N1 (Clontech) using HindIII and ApaI. Clathrin-lightchain-DsRed was a gift from W. Almers (Vollum Institute, USA) and previously described 35 . Photoactivatable (PA)-mCherry1-clathrin-light-chain was a gift from M. Davidson (Florida State University, USA). Clathrin-light-chain-TagBFP was generated by PCR amplifying clathrin light chain and subcloning into pTagBFP (Evrogen) using EcoRI and ApaI. β-Arrestin-2-PA-mCherry1 was generated by subcloning β-arrestin-2 into pPA-mCherry1-N1 (gift from M. Davidson), using HindIII and ApaI. A non-targetable mutant (NTM) of β-arrestin-2 (β-arrestin-2-GFP-NTM) was generated using site-directed mutagenesis (Phusion Site-Directed Mutagenesis Kit, Thermo Scientific) of β-arrestin-2-GFP to introduce synonymous mutations in the nucleotide sequence targeted by ARB2_10 siRNA using primers 5 -CGCCCAGTTCCACGTTCTGTA-3 and 5 -CTCAGGTCGAGCAGGACGA CCAGGTGT-3 . To generate a non-targetable mutant (NTM) of clathrin heavy chain (CHC17), clathrin-NTM was generated using a gBlock (IDT) to introduce six synonymous mutations in the nucleotide sequence targeted by the CHC17 siRNA. The clathrin-NTM gBlock was inserted into CHC17 using PmlI and BsteII. All stars negative control (non-silencing) and silencing siRNAs were obtained from Qiagen. The sense-strand, silencing siRNA sequences are as follows: β-arrestin-2 (ARB2_10), 5 -CGAACAAGAUGACCAGGUATT-3 ; clathrin heavy chain, 5 -GCAAUGAGCUGUUUGAAGATT-3 .
Transfections were carried out using Lipofectamine 2000 or RNAi-Max (Life Technologies) for cDNA or siRNA, respectively, according to the manufacturer's protocol. For DNA expression, cells were transfected 48 h before experiments. For siRNA knockdown, cells were transfected with siRNA constructs 72 h before experiments. For siRNA rescue experiments, cells were transfected with the indicated siRNA construct 72 h before experiments and subsequently transfected with a plasmid containing synonymous mutations in the region targeted by siRNA (non-targetable mutants). Experiments were performed 48 h after DNA rescue construct transfection.
Flow cytometric analysis of receptor endocytosis. The flow cytometric assays to measure endocytosis of receptor surface fluorescence were carried out as previously described 36 . Surface fluorescence of FLAG-β1AR-or FLAG-β2AR-expressing HEK 293 cells was used to measure receptor endocytosis. Cells were incubated with 10 µM isoproterenol for the indicated times at 37 • C to drive receptor internalization and were subsequently washed with ice-cold PBS, then mechanically lifted and incubated with 1µg ml −1 Alexa647 (Life Technologies)-conjugated M1 anti-FLAG monoclonal antibody (Sigma F-3040) at 4 • C for 45 min. Mean fluorescence intensity of 10,000 cells per technical replicate was measured using a FACSCalibur instrument (Becton Dickinson). At least three independent experiments were performed in triplicate for each condition.
Live cell total internal reflection fluorescence microscopy (TIR-FM) imaging. TIR-FM was performed at 37 • C using a Nikon Ti-E inverted microscope equipped for through-the-objective TIR-FM and outfitted with a temperature-, humidityand CO 2 -controlled chamber (Okolab). Images were obtained with an Apo TIRF 100×, 1.49 numerical aperture objective (Nikon) with solid-state lasers of 405, 488, 561 and 647 nm (Keysight Technologies). An Andor iXon DU897 EMCCD camera controlled by NIS-Elements 4.1 software was used to acquire image sequences every 2 s for 10 min. Cells were transfected as indicated according to the manufacturer's protocol 48 h before imaging and then plated on poly-L-lysine (0.0001%, Sigma)-coated 35-mm glass-bottomed culture dishes (MatTek Corporation) 24 h before imaging. Cells were labelled with M1 monoclonal FLAG antibody (1:1,000, Sigma F-3040) conjugated to Alexa647 dye (Life Technologies) for 10 min at 37 • C before imaging, washed, and imaged live in DMEM without phenol red (UCSF Cell Culture Facility) supplemented with 30 mM HEPES, pH 7.4 (UCSF Cell Culture Facility). Cells were treated with 10 µM dobutamine (Tocris Bioscience) or 10 µM isoproterenol (Sigma) to activate either FLAG-β1ARs or FLAG-β2ARs, respectively, at frame 10 of 301 image sequences. For experiments with the β1AR-selective antagonist CGP20712A (Tocris Bioscience), cells were pretreated for 15 min with 500 nM CGP20712A, and then treated with 10 µM dobutamine at frame 10 of 301 image sequences. At least two independent experiments were performed for all live cell TIR-FM imaging.
TIR-FM image analysis. Acquired image sequences were saved as stacks of 16-bit TIFF files. All quantitative image analysis was performed on unprocessed images using ImageJ and Fiji software 37, 38 . To quantify change in receptor fluorescence over time in TIR-FM images, fluorescence values were measured in five randomly selected regions of interest (ROIs) in the cell over the entire stack. An area of the coverslip lacking cells was used to estimate background fluorescence. Fluorescence values of the five ROIs were background subtracted, averaged, and normalized to initial fluorescence values before agonist addition. Minimal bleed-through and photobleaching was verified using single-labelled and untreated samples, respectively. Line scan analysis of receptor, β-arrestin, or clathrin fluorescence from the shown line was carried out using the ImageJ plot profile function to measure pixel values from this line. To calculate fluorescence enrichment at CCSs, a mask of CCSs was generated using a thresholded average image of the clathrin channel. Enrichment at CCSs for receptor and arrestin was measured as the difference between the average fluorescence in the mask and average fluorescence outside the thresholded structures. Confidence intervals of enrichment at CCSs were determined by generating 2,000 unique randomized masks, where the position and orientation of the thresholded CCSs is distinct from the original mask or other randomized masks. Enrichment was calculated for every randomization over time, the 2,000 values sorted for every time point, and the 5% lowest and highest values used to determine a confidence interval for significant enrichment.
Lifetimes of β-arrestin-2 clusters after β1AR or β2AR activation were measured blindly by calculating the number of frames between cluster appearance and disappearance from the TIR-FM field. Only clusters whose appearance and disappearance could clearly be observed were included in the analysis. The cmeAnalysis software package was used to measure the CCP lifetimes.
Live cell photoactivated localization microscopy (PALM) imaging and analysis. PALM was performed at 37 • C using a Nikon Ti-E inverted microscope equipped for through-the-objective TIR-FM and outfitted with a temperature-, humidityand CO 2 -controlled chamber (Okolab). Images were obtained with an Apo TIRF 100×, 1.49 numerical aperture objective (Nikon) with solid-state lasers of 405, 488, 561 and 647 nm (Keysight Technologies) as light sources. An Andor iXon DU897 EMCCD camera controlled by NIS-Elements 4.1 software was used to acquire 5,000 periods with continuous activation by 405 nm light. Cells were transfected as indicated according to the manufacturer's protocol 48 h before imaging and then plated on poly-L-lysine (0.0001%, Sigma)-coated 35-mm glass-bottomed culture dishes (MatTek Corporation) 24 h before imaging. Cells were labelled with M1 monoclonal FLAG antibody (1:1,000, Sigma F-3040) conjugated to Alexa647 dye (Life Technologies) for 10 min at 37 • C, washed one time with imaging media (20 mM HEPES, 135 mM NaCl, 5 mM D-glucose, 5 mM KCl, 0.4 mM MgCl 2 , 1.8 mM CaCl 2 , pH 7.4), and imaged live in imaging media. NIS-Elements software (Nikon) was used to resolve and analyse the images. Full-width at half-maximum calculations were used to measure the size of the super-resolved structures. PALM imaging experiments were performed at least three independent times.
Live cell structured illumination microscopy (SIM) imaging and analysis. SIM was performed using a Nikon Ti-E inverted microscope equipped with sapphire lasers of 488 and 561 nm (Coherent). Images were obtained using an Apo TIRF 100× 1.49 objective (Nikon) and a 3D EX V-R SIM grating (Nikon). An Andor iXon DU897 EMCCD camera controlled by NIS-Elements 4.12 software was used to acquire images. Cells were transfected as indicated according to the manufacturer's protocol 48 h before imaging and then plated on poly-L-lysine (0.0001%, Sigma)-coated 35-mm glass-bottomed culture dishes (MatTek Corporation) 24 h before imaging. Cells were imaged live in DMEM without phenol red (UCSF Cell Culture Facility) supplemented with 30 mM HEPES, pH 7.4 (UCSF Cell Culture Facility). NIS-Elements 4.12 software was used to reconstruct images and analyse the images. Full-width at half-maximum calculations were used to measure the size of the observed structures in the reconstructed images. SIM imaging experiments were performed three independent times.
Fluorescence recovery after photobleaching of immobilized receptors. To limit receptor diffusion in the plasma membrane, cells transfected with SEP-β1ARs were treated with a polyclonal rabbit anti-GFP antibody (1:100, Life Technologies A-11122) for 15 min at 37 • C to group multiple receptors together as described previously 21 . Cells were then washed and imaged live in DMEM without phenol red (UCSF Cell Culture Facility). Fluorescence recovery after photobleaching was performed at 37 • C using a Nikon Ti inverted microscope equipped with a temperature-, humidity-and CO 2 -controlled chamber (Okolab). Images were obtained with an Apo TIRF 100×, 1.49 numerical aperture objective (Nikon) with 488 and 561 nm solid-state lasers (Keysight Technologies). An Andor Zyla CMOS camera controlled by MicroManager software was used to acquire image sequences. To verify that receptor mobility was slowed after antibody addition, a Rapp Optoelectronic UGA-40 photobleaching system was used to photobleach DOI: 10.1038/ncb3307 SEP-β1ARs on an area of the plasma membrane with a 473 laser (Vortran). Cells were imaged every second for 5 min to monitor fluorescence recovery after photobleaching. All quantitative image analysis was performed on unprocessed images using ImageJ software. Mean fluorescence intensity was measured in the photobleached region, background subtracted using an area outside the cell, and normalized to initial fluorescence. Imaging experiments were performed three independent times.
Transferrin uptake assay. Cells expressing FLAG-labelled receptors or empty vector plasmid were first incubated in serum-free medium for 90 min at 37 • C and subsequently in serum-free media containing 200 µg ml −1 Alexa647-transferrin (Invitrogen) and 10 µM receptor-specific agonist for the indicated time at 37 • C to activate the indicated GPCRs and allow for constitutive uptake of Alexa647-transferrin. After washing with ice-cold PBS, cells were incubated in acid-wash buffer (20 mM sodium acetate buffer, 1 mM CaCl 2 , 150 mM NaCl, pH 4.8) on ice for 5 min to remove surface-bound transferrin. Cells were then mechanically lifted in PBS for 15 min at 4 • C. Mean fluorescence intensity of 5,000 cells was measured using a FACSCalibur instrument (Becton Dickinson). At least three independent experiments were performed in triplicate for each condition.
ERK1/2 activation assays. To measure activation of ERK1/2, western blot analysis and fixed-cell flow cytometry were used. For both methods, cells stably expressing FLAG-β1ARs or FLAG-β2ARs were serum starved for 18 h before assay, incubated with the indicated agonist for the indicated times at 37 • C, and then washed on ice with ice-cold PBS. For cells treated with Dyngo-4a, serum-starved cells were pretreated with 30 µM Dyngo-4a for 15 min, treated with 10 µM dobutamine for the indicated times at 37 • C in the presence of 30 µM Dyngo-4a, and then washed on ice with ice-cold PBS. For western blot analysis, cells were directly lysed in sample buffer (NuPAGE LDS Sample Buffer (Life Technologies), 100 mM dithiothreitol), sonicated three times for 10 s, boiled, separated by SDS-PAGE (Life Technologies) and transferred to a nitrocellulose membrane that was blocked with TBS Odyssey blocking buffer (LI-COR) for one hour at room temperature and then incubated overnight at 4 • C with a mouse anti-ERK1/2 primary antibody (1:2,000, Cell Signaling 4696) and a rabbit anti-phosphorylated-ERK1/2 primary antibody (1:2,000, Cell Signaling 4370). Membranes were washed three times for 5 min in TBS-Tween (0.1% v/v) and incubated with a 680-labelled antirabbit secondary antibody (1:5,000, LI-COR 926-68073) and an 800-labelled anti-mouse secondary antibody (1:5,000, LI-COR 926-32212) for one hour at room temperature. Membranes were washed three times for 5 min in TBSTween (0.1% v/v), imaged using an Odyssey Infrared Imaging System (LI-COR) in the linear range, and quantified by measuring band intensity, background subtracting, and normalizing the phosphorylated ERK1/2 band intensity to the total ERK1/2 band intensity. At least three independent experiments were performed for each condition.
For fixed-cell flow cytometric analysis, cells were fixed on ice for 10 min using 4% cytofix solution (BD Cytofix), lifted with a cell scraper, and transferred to a 96-well plate. Cells were permeabilized using cold methanol and incubated overnight at −20 • C. Cells were then washed with staining buffer (Ca + /Mg + PBS, 2% FBS, 2 mM EDTA), rehydrated, and incubated for one hour at room temperature with a mouse anti-ERK1/2 primary antibody (1:200, Cell Signaling 4696) and a rabbit anti-phosphorylated ERK1/2 primary antibody (1:200, Cell Signaling 4370) diluted in staining buffer. Cells were then washed three times with staining buffer and incubated with a 488-labelled anti-mouse secondary antibody (1:100, Life Technologies A-21202) and a 647-labelled anti-rabbit secondary antibody (1:100, Life Technologies A-21245) for 30 min at room temperature. Cells were washed three times with staining buffer, separated with a cell strainer, and mean fluorescence intensity of 5,000 cells was measured using a FACSCalibur instrument (Becton Dickinson). ERK1/2 activation was determined by normalizing phosphorylated ERK1/2 mean fluorescence to total ERK1/2 mean fluorescence. Mean fluorescence intensity of 5,000 cells was measured using a FACSCalibur instrument (Becton Dickinson). At least three independent experiments were performed in triplicate for each condition.
Statistical analysis. Quantitative data are expressed as the mean and error bars represent the standard error of the mean (s.e.m.) unless otherwise indicated. The statistical significance between conditions was analysed using a two-tailed t-test and calculated using Prism 6.0 software (GraphPad Software). P values were considered to be significant if P < 0.05 when compared with control or mock treatment conditions. P values >0.05 are indicated in the figures as not significant (NS) . Exact values of all significant P values are specified in the appropriate figure legends. All experiments and representative data shown were repeated at least twice and performed with independent samples. Table 1 , and uncropped original scans of western blots are shown in Supplementary Fig. 6 . Error bars correspond to SEM. Panels (c) and (f) are representative data from 3 independent experiments. Uncropped original scans of western blots are shown in Supplementary Fig. 6 .
Supplementary Figure 6 Unprocessed scans of western blots accompanied by size markers. Black boxes delineate the region presented in the indicated figures. Images were obtained using a Licor Odyssey scanner, acquired using Image Studio 2.0, and analyzed using ImageStudioLite. 
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